Compare Enveric Biosciences Inc (ENVB) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Synopsys, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Synopsys, Inc. trades at $419.54 (market cap $81.43B). The key difference: Synopsys, Inc. is far larger — about 15306.4× Enveric Biosciences Inc's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | SNPS | |
|---|---|---|
Market Cap | $5.32M | $81.43B |
Sector | Health | Technology |
52-Week High | $17.40 | $645.59 |
52-Week Low | $1.28 | $380.47 |
Enterprise Value | $408.82K | $89.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Synopsys (SNPS) trades at $425.81, down 1.85% amid bearish technical signals, though it maintains strong analyst support with 82.8% buy ratings and a $559.50 consensus target. The company shows consistent earnings beats and robust revenue growth to $7.05B in 2025, though profitability metrics like net margin (8.91%) and ROE (3.83%) are tempered by high valuations (P/E 97.32). Recent news highlights its strategic pivot to AI-driven design tools and the integration of Ansys, positioning it as a key enabler in the semiconductor ecosystem.
The outlook remains positive given SNPS's strategic positioning in AI and semiconductor design, with significant upside to analyst targets. Risks include execution challenges from the Ansys integration, competitive pressures, and sensitivity to semiconductor cycles. Investors should weigh high valuation multiples against growth potential in the expanding AI market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
